Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 17/20 | 0.61 |
| ▸ | CTSS | P25774 | 9/20 | 0.61 |
| ▸ | CTSL | P07711 | 8/20 | 0.61 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216747 | 1.00 | CTSB (0.61) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL12432975 | 0.88 | CTSS (0.68) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL31095613 | 0.88 | CTSS (0.68) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL6218646 | 0.85 | CTSS (0.51) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL6218643 | 0.85 | CTSS (0.51) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL6213718 | 0.85 | CTSB (0.47) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL6218326 | 0.85 | CTSB (0.47) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL3629077 | 0.77 | SLC7A5 (0.52) | CTSBCTSSCTSLCTSK | |
| SCHEMBL8438333 | 0.77 | PPARA (0.63) | CTSBCTSSCTSLCTSKPPARA | |
| SCHEMBL3992230 | 0.77 | SLC7A5 (0.52) | CTSBCTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1283825-B1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-6812237-B2 | (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1283825-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | Novartis AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087828-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | CTSS, CTSV, CTSF | CTSB 4/4885CTSS 1/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.